scholarly journals Avascular necrosis of bone in childhood cancer patients: a possible role of genetic susceptibility

2015 ◽  
Vol 116 (05) ◽  
pp. 289-295
Author(s):  
L. Geczova ◽  
A. Soltysova ◽  
J. Gecz ◽  
S. Sufliarska ◽  
J. Horakova ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Genetic Susceptibility ◽  
Cancer Patients ◽  
Avascular Necrosis ◽  
Avascular Necrosis Of Bone

scholarly journals Avascular necrosis of bone after renal transplantation: role of parathyroid hormone and vitamin D.

BMJ ◽  
1978 ◽  
Vol 2 (6138) ◽  
pp. 664-665 ◽  
Author(s):  
C M Page ◽  
B Hulme ◽  
S E Papapoulos ◽  
J L O'Riordan
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Renal Transplantation ◽  
Avascular Necrosis ◽  
Avascular Necrosis Of Bone

scholarly journals Avascular Necrosis of Bone following Chemotherapy in Cancer Patients with Coagulopathy: Report of Two Cases

2018 ◽  
Vol 11 (1) ◽  
pp. 185-190 ◽  
Author(s):  
Hui-Ching Hsu ◽  
Tzu-Yao Liao ◽  
Dave Wei-Chih Chen ◽  
Yu-Hsiang Juan ◽  
Chuang-Chi Liaw
Keyword(s):  
Cancer Patients ◽  
Solid Tumors ◽  
Avascular Necrosis ◽  
Hip Arthroplasty ◽  
Groin Pain ◽  
Paraneoplastic Syndromes ◽  
The Other ◽  
Thromboembolic Complications ◽  
Femoral Heads ◽  
Avascular Necrosis Of Bone

We report 2 cases of patients with solid tumors and coagulopathy who experienced avascular necrosis (AVN) of the bone following chemotherapy. Both cases exhibited nontraumatic bilateral AVN of the femoral heads, and one also showed bilateral AVN of the humeral heads. One case had multiple thromboembolic complications, including pulmonary obstructive syndrome and paraneoplastic pain. The other showed multiple paraneoplastic syndromes, with hypercalcemia and thrombocytosis. Groin pain and claudication of the lower extremities developed and persisted. Both patients eventually received bilateral hip arthroplasty due to AVN of both femoral heads.

scholarly journals إستراتيجية العلاقات العامة في نشر الوعي الصحي : دراسة تطبيقية على مرضى سرطان الأطفال بالخرطوم

2021 ◽  
Vol 8 (2) ◽  
Author(s):  
الفكي منتصر سعد عمر
Keyword(s):  
Public Relations ◽  
Childhood Cancer ◽  
Cancer Patients ◽  
Arab World ◽  
Raising Awareness ◽  
The Future

إستراتيجية العلاقات العامة في نشر الوعي الصحي : دراسة تطبيقية على مرضى سرطان الأطفال بالخرطوم Hundred and twenty (120 ) children under the age of fifteen per million suffer from cancer annually in the Arab world and this percentage does not constitute more than the of the injured adults, although it needs attention to this phenomenon, and to do our utmost in the fighting against this disease to be avoided or to decrease it's effect, because children are all the future, so the importance of this study was to raise awareness of the fight against this disease. The research aims at taking the role of public relations in charities'stsablish that deal with issues of childhood cancer patients' andin raising awareness to combat declarewar against this disease and to identify the programs carried out by public relations in the fight against this disease, .The study shows the exact of response to there programs and the means used by the establish with to cary at the against this decrease, the study shows some impact results

scholarly journals Adverse Factors and the Role of Cisplatin and Vinca Alkaloids for Hearing Impairment in Childhood Cancer Patients and Survivors

2017 ◽  
Vol 24 (2) ◽  
pp. 121-129
Author(s):  
Min Woo Hur ◽  
Seung Min Hahn ◽  
In Seok Moon ◽  
Ju Yeon Lim ◽  
Seul Mi Lee ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Cancer Patients ◽  
Hearing Impairment ◽  
Vinca Alkaloids

scholarly journals Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study (Preprint)

2018 ◽  
Author(s):  
Eva Clemens ◽  
Annelot JM Meijer ◽  
Linda Broer ◽  
Thorsten Langer ◽  
Anne-Lotte LF van der Kooi ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Childhood Cancer ◽  
Candidate Gene ◽  
Genetic Susceptibility ◽  
Cancer Patients ◽  
Hearing Impairment ◽  
Genome Wide Association ◽  
Candidate Gene Approach ◽  
Cranial Radiotherapy ◽  
Genome Wide

BACKGROUND Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development. Although treatment-related risk factors for hearing loss following childhood cancer treatment have been identified, the individual variability in toxicity of adverse effects after similar treatment between childhood cancer patients suggests a role for genetic susceptibility. Currently, 12 candidate gene approach studies have been performed to identify polymorphisms predisposing to platinum-induced ototoxicity in children being treated for cancer. However, results were inconsistent and most studies were underpowered and/or lacked replication. OBJECTIVE We describe the design of the PanCareLIFE consortium’s work packages that address the genetic susceptibility of platinum-induced ototoxicity. METHODS As a part of the PanCareLIFE study within the framework of the PanCare consortium, we addressed genetic susceptibility of treatment-induced ototoxicity during and after childhood cancer treatment in a large European cohort by a candidate gene approach and a genome-wide association screening. RESULTS This study included 1124 survivors treated with cisplatin, carboplatin, or cranial radiotherapy for childhood cancer, resulting in the largest clinical European cohort assembled for this late effect to date. Within this large cohort we defined a group of 598 cisplatin-treated childhood cancer patients not confounded by cranial radiotherapy. The PanCareLIFE initiative provided, for the first time, a unique opportunity to confirm already identified determinants for hearing impairment during childhood cancer using a candidate gene approach and set up the first international genome-wide association study of cisplatin-induced direct ototoxicity in childhood cancer patients to identify novel allelic variants. Results will be validated in an independent replication cohort. Patient recruitment started in January 2015 and final inclusion was October 2017. We are currently performing the analyses and the first results are expected by the end of 2019 or the beginning of 2020.  CONCLUSIONS Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies. INTERNATIONAL REGISTERED REPOR DERR1-10.2196/11868

130: Role of Calcium Intake on Bone Mineral Density in Rostate Cancer Patients Under Androgen Deprivation Therapy

2006 ◽  
Vol 175 (4S) ◽  
pp. 41-42
Author(s):  
Anna Orsola ◽  
Jacques Planas ◽  
Carlos Salvador ◽  
José M. Abascal ◽  
Enrique Trilla ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Bone Mineral ◽  
Calcium Intake ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
Rostate Cancer

CASSINI and AVERT – future role of NOACs for VTE prevention in cancer patients?

VASA ◽  
2020 ◽  
Vol 49 (3) ◽  
pp. 247-248
Author(s):  
Leonie Kühnemund ◽  
Eva Freisinger
Keyword(s):  
Cancer Patients ◽  
Future Role
Sign in / Sign up

Export Citation Format

Share Document